Community Code Relating to Medicinal Products for Human Use
The consolidated EU code for human medicines: the marketing-authorisation requirement and its dossier, manufacturing and wholesale-distribution authorisations, labelling and package-leaflet requirements, advertising rules, and the pharmacovigilance obligations of the authorisation holder.
Always verify against the current published text before relying on it for a submission or inspection.
Scope & applicability
Human medicinal products placed on the EU market through national, mutual-recognition and decentralised routes; the centralised procedure is governed by Regulation (EC) No 726/2004 alongside it. As a Directive it binds through national transposition, so the operative text a company complies with is its Member State law.
Key requirements
- Article 6 — no medicinal product may be placed on the market without an authorisation
- Article 40 — manufacture requires a manufacturing authorisation; Article 46 sets the holder’s obligations, including the Qualified Person
- Title V — labelling and package leaflet, including the readability and language requirements
- Title VII — wholesale distribution; Title VIIIa — advertising, restricted to the terms of the summary of product characteristics
Implementation tips
- Read it as transposed: the Directive sets the requirement, national law sets the text an inspector cites, and the two can differ in detail
- The 2026 EU pharmaceutical package would replace this Directive and Regulation (EC) No 726/2004. As of August 2026 the compromise texts are published and adoption is pending, so 2001/83/EC as amended remains the instrument in force — plan against it, and watch the package rather than citing it
Revision notes
Amended many times since 2001, notably by Directive 2010/84/EU (pharmacovigilance) and Directive 2011/62/EU (falsified medicines). A full replacement is proposed under the 2026 EU pharmaceutical package: trilogue concluded December 2025, compromise texts published by the Council March 2026, final adoption pending as of August 2026.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
Directive 2001/83/EC: frequently asked questions
Quick answers to common questions about Directive 2001/83/EC.
What is Directive 2001/83/EC?
Directive 2001/83/EC — Community Code Relating to Medicinal Products for Human Use — is a regulation issued by the European Commission — EudraLex (European Union). The consolidated EU code for human medicines: the marketing-authorisation requirement and its dossier, manufacturing and wholesale-distribution authorisations, labelling and package-leaflet requirements, advertising rules, and the pharmacovigilance obligations of the authorisation holder.
Who does Directive 2001/83/EC apply to?
Human medicinal products placed on the EU market through national, mutual-recognition and decentralised routes; the centralised procedure is governed by Regulation (EC) No 726/2004 alongside it. As a Directive it binds through national transposition, so the operative text a company complies with is its Member State law.
What are the key requirements of Directive 2001/83/EC?
EC Directive 2001/83/EC requires, among other things: Article 6 — no medicinal product may be placed on the market without an authorisation; Article 40 — manufacture requires a manufacturing authorisation; Article 46 sets the holder’s obligations, including the Qualified Person; Title V — labelling and package leaflet, including the readability and language requirements; Title VII — wholesale distribution; Title VIIIa — advertising, restricted to the terms of the summary of product characteristics.
When was Directive 2001/83/EC last updated?
The current version of Directive 2001/83/EC dates from December 2022. Amended many times since 2001, notably by Directive 2010/84/EU (pharmacovigilance) and Directive 2011/62/EU (falsified medicines). A full replacement is proposed under the 2026 EU pharmaceutical package: trilogue concluded December 2025, compromise texts published by the Council March 2026, final adoption pending as of August 2026.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.